
Camp4 Therapeutics rose 3.8% from $3.95 to $4.10, behind the S&P 500's +10.6%. Its worst day was Jan 20 (−21.0%), and its low came Nov 21 at $2.90.
Nov 18, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Camp4 Therapeutics closed at its lowest level of the year, 26.6% below where the year started.
−17.4% · S&P 500 +1.0%
Camp4 Therapeutics shares rose 26.0%, while the S&P 500 fell 0.1%.
+26.0% · S&P 500 −0.1%
Story events cover the past 12 months · Times ET
Camp4 Therapeutics closed at its highest level of the year, 80.5% above where the year started.
+1.7% · S&P 500 −1.1%
Camp4 Therapeutics shares fell 21.0%, while the S&P 500 fell 2.0%.
−21.0%, the year's worst day · S&P 500 −2.0%
EPS of $-0.87 missed the $-0.30 estimate on $348,000.00 revenue (est. $538,000.00).
+12.5% · S&P 500 −0.6%
EPS of $-0.32 missed the $-0.21 estimate on $1.3M revenue (est. $1.2M).
+2.8% · S&P 500 +0.8%
Camp4 Therapeutics shares rose 22.0%, while the S&P 500 rose 1.4%.
+22.0% · S&P 500 +1.4%
EPS of $-0.58 missed the $-0.22 estimate on $1.8M revenue (est. $1.8M).
+20.9% · S&P 500 −0.2%
Camp4 Therapeutics shares rose 18.2%, while the S&P 500 rose 1.0%.
+18.2% · S&P 500 +1.0%
EPS of $-0.37 missed the $-0.21 estimate on $1.9M revenue (est. $1.8M).
+9.1% · S&P 500 +0.3%
Where it ended: a close of $4.10 on Nov 18, 2026. Up next: Q4 2026 earnings on Mar 4, 2027 (EPS est. $-0.19, revenue est. $2.1M).
Nothing in the past 12 months.
All CAMP dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CAMP and SPY from Benzinga historical bars. Not investment advice.